Altamira Therapeutics Ltd. (CYTOF)
OTCMKTS
· Delayed Price · Currency is USD
0.1000
0.00 (0.00%)
Apr 28, 2025, 4:00 PM EDT
Altamira Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2014 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2014 - 2018 |
| Cash & Equivalents | 0.07 | 0.73 | 0.02 | 1.08 | 12.73 | 1.43 | Upgrade
|
| Cash & Short-Term Investments | 0.07 | 0.73 | 0.02 | 1.08 | 12.73 | 1.43 | Upgrade
|
| Cash Growth | 20.51% | 4303.95% | -98.46% | -91.52% | 790.04% | -73.91% | Upgrade
|
| Accounts Receivable | - | - | 0.01 | 0.02 | - | - | Upgrade
|
| Other Receivables | 0.12 | 0.09 | 0.82 | 0.73 | 0.07 | 0.24 | Upgrade
|
| Receivables | 0.12 | 0.09 | 0.82 | 0.75 | 0.07 | 0.24 | Upgrade
|
| Inventory | - | - | 0.01 | 0.92 | - | - | Upgrade
|
| Prepaid Expenses | 0.08 | 0.08 | 0.05 | 0.15 | 0.12 | 0.13 | Upgrade
|
| Other Current Assets | 0.26 | 0.55 | 1.01 | 1.59 | 0.21 | 0.65 | Upgrade
|
| Total Current Assets | 0.52 | 1.45 | 1.91 | 4.49 | 13.13 | 2.45 | Upgrade
|
| Property, Plant & Equipment | 0.42 | 0.1 | 0.48 | 0.62 | 0.05 | 0.07 | Upgrade
|
| Long-Term Investments | 2.5 | 2.97 | 0.21 | 0.22 | - | - | Upgrade
|
| Other Intangible Assets | 4.63 | 4.62 | 4.21 | 15.7 | 10.3 | 6.99 | Upgrade
|
| Other Long-Term Assets | - | - | - | - | - | 0.02 | Upgrade
|
| Total Assets | 8.07 | 9.14 | 6.82 | 21.03 | 23.51 | 9.53 | Upgrade
|
| Accounts Payable | 0.53 | 0.49 | 5.16 | 3.89 | 0.82 | 0.94 | Upgrade
|
| Accrued Expenses | 0.58 | 0.41 | 2.14 | 1.15 | 1.62 | 1.38 | Upgrade
|
| Short-Term Debt | - | - | 6.35 | - | 0.59 | - | Upgrade
|
| Current Portion of Leases | 0.12 | 0.12 | 0.13 | 0.13 | - | - | Upgrade
|
| Other Current Liabilities | - | 0.03 | 0.16 | 0.17 | 0.4 | 0.03 | Upgrade
|
| Total Current Liabilities | 1.23 | 1.06 | 13.93 | 5.33 | 3.42 | 2.35 | Upgrade
|
| Long-Term Leases | 0.3 | - | 0.37 | 0.51 | - | - | Upgrade
|
| Long-Term Unearned Revenue | - | - | 1.01 | - | - | - | Upgrade
|
| Long-Term Deferred Tax Liabilities | - | - | 0.14 | 0.16 | 0.14 | 0.15 | Upgrade
|
| Other Long-Term Liabilities | - | - | - | 0 | 0.01 | 0 | Upgrade
|
| Total Liabilities | 1.75 | 1.47 | 15.81 | 6.73 | 4.55 | 3.29 | Upgrade
|
| Common Stock | 0.01 | 0 | 0.26 | 0.16 | 0.13 | 1.7 | Upgrade
|
| Additional Paid-In Capital | - | 23.87 | 208.31 | 206.79 | 200.32 | 162.31 | Upgrade
|
| Retained Earnings | 1.26 | -21.43 | -217.84 | -192.72 | -181.56 | -157.75 | Upgrade
|
| Comprehensive Income & Other | 5.05 | 5.22 | 0.28 | 0.07 | 0.07 | -0.03 | Upgrade
|
| Shareholders' Equity | 6.32 | 7.67 | -8.99 | 14.3 | 18.95 | 6.23 | Upgrade
|
| Total Liabilities & Equity | 8.07 | 9.14 | 6.82 | 21.03 | 23.51 | 9.53 | Upgrade
|
| Total Debt | 0.43 | 0.12 | 6.85 | 0.63 | 0.59 | - | Upgrade
|
| Net Cash (Debt) | -0.36 | 0.61 | -6.83 | 0.45 | 12.13 | 1.43 | Upgrade
|
| Net Cash Growth | - | - | - | -96.31% | 748.62% | -64.45% | Upgrade
|
| Net Cash Per Share | -0.26 | 1.25 | -150.00 | 13.53 | 807.00 | - | Upgrade
|
| Filing Date Shares Outstanding | 2.67 | 2.24 | 0.35 | 0.04 | 0.03 | 0.01 | Upgrade
|
| Total Common Shares Outstanding | 2.67 | 1.48 | 0.06 | 0.04 | 0.03 | 0.01 | Upgrade
|
| Working Capital | -0.7 | 0.4 | -12.02 | -0.84 | 9.71 | 0.1 | Upgrade
|
| Book Value Per Share | 2.37 | 5.19 | -152.40 | 382.25 | 664.06 | 604.22 | Upgrade
|
| Tangible Book Value | 1.69 | 3.05 | -13.2 | -1.4 | 8.65 | -0.75 | Upgrade
|
| Tangible Book Value Per Share | 0.63 | 2.06 | -223.77 | -37.49 | 303.11 | -73.02 | Upgrade
|
| Machinery | - | 0.7 | 0.64 | 0.64 | 0.66 | 0.61 | Upgrade
|
Updated Sep 24, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.